Friday, April 16, 2021

Amgen Completes Five Prime Therapeutics Deal

Thousand Oaks-based Amgen said this morning that it has successfully completed its $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Amgen paid $38.00 per share in cash for Five Prime Therapeutics. Five Prime's programs include bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer.

---